Emerging evidence indicates that periodontal pathogens, particularly P.g., may undermine efficacy of conventional anti-cancer therapies by promoting chemoresistance and enhancing tumor adaptability via pathways regulated by Notch1 and IL-6 [46, 105, 106, 126]. The gene discussed is NOTCH1; the disease is cancer.